Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02755207|
Recruitment Status : Recruiting
First Posted : April 28, 2016
Last Update Posted : April 24, 2018
|Condition or disease|
|Acute Coronary Syndrome|
The present study is a single-center, prospective diagnostic study among patients presenting to the ED or ICU within 24 h of onset of chest pain suggestive of suspected ACS.
We propose to construct the biobank of ACS and evaluate the potential diagnostic value of circulating microRNAs compared with cTnI for suspected ACS patients. All the patients are to be followed up for 6 months. Final diagnosis was made by an expert panel cardiologist, based on all available clinical information including cTnI measurements, ECG, coronary angiography, cardiac exercise tests and information from hospital discharge letters.
The concentrations of microRNAs will be evaluated by quantitative reverse transcription PCR, using highly specific primers and hybridization probes.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Suspected ACS group
Patients admitted to the hospital with the diagnosis of ACS
Blank control group
Patients admitted to the hospital without the diagnosis of ACS
- Evaluate the diagnostic value of microRNAs in qPCR，in ACS [ Time Frame: Day 7 ]
- Evaluate the prognostic value of microRNAs in ACS [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02755207
|Contact: bin firstname.lastname@example.org|
|Contact: huimin email@example.com|
|Ethics Committee of Xinhua Hospital||Recruiting|
|Shanghai, Shanghai, China, 200092|
|Contact: Guangyu Chen, PhD +86-02125076143 firstname.lastname@example.org|